ANALISIS CD4 PADA PENATALAKSANAAN PASIEN KOINFEKSI HIV-TB

Nursin Abd. Kadir, Nurhayana Sennang, Hardjoeno .

Abstract


The Human Immunodeficiency Virus (HIV) epidemic has increased the burden of tuberculosis (TB) among young adults, especially in
populations where the prevalence of TB infection is high like Indonesia. TB is the most common opportunistic infection on HIV patients
(50%) in developing countries. CD4 also known as T helper lymphocytes are coordinators of body`s immune response, and it has been
declining in HIV infection and be worsened by TB infection. CD4 count are standard laboratory marker of disease progression to followup
and
prognosis
antiretroviral
therapy
in
HIV
infection.
Aims
to
see
the
value
of
CD4
count
of
HIV-TB
co-infected
patients
before
and

after
antituberculosis
together
with
antiretroviral
therapy.
A
longitudinal
study
was
conducted
by
collecting
secondary
data
from
the

medical
record
and
the
results
of
Clinical
Pathology
Laboratory
of
HIV-TB
co-infected
patients
at
Wahidin
Sudirohusodo
Hospital
period

July
2007–August
2008.
Data
were
analyzed
by
Wilcoxon
Signed
Rank
Test
and
Mann
Whitney
Test
with
a
=
0.05.
Total
samples
(n)

were
20
patients
(14
patients
with
continous
therapy
and
6
uncontinous
therapy).
We
found
different
means
between
CD4
count
before

and
after
Therapy.
CD4
count
before
therapy
was
71.15
±
81.04
and
after
therapy
was
114.95
±
109.71
(p
=
0.089)
with
Wilcoxon

Signed
Rank
Test.
The
analyzed
were
continued
by
divided
samples
in
continous
group
compared
with
uncontinous
group
therapy.
The

result
showed
the
CD4
alteration
in
continous
group
was
853.8%
and
uncontinous
group
was
-56.6%
where
p
=
0.000
(Mann
Whitney

test).
CD4
count
has
increased
significantly
in
HIV-TB
co-infected
patients
8.5
fold
from
CD4
baseline
with
continous
therapy
and
the
uncontinous one has decreased 0.5 fold from CD4 baseline.


Keywords


HIV-TB Co-infected patients, CD4 count, continous therapy, uncontinous therapy

Full Text:

PDF


DOI: http://dx.doi.org/10.24293/ijcpml.v16i1.991

Refbacks

  • There are currently no refbacks.